Given the important role of HMGB1 in MM initiation and progression, and the current lack of effective therapeutic options for MM patients, we tested the hypothesis that EP may impair mesothelial cell transformation and suppress the malignant phenotype of MM. Here, HMGB1 is linked to Miyoshi myopathy.